Scientific Publications

2018 | 2017 | 2016 | 2015 | 2014

2013 | 2012 | 2011 | 2010



Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

New England Journal of Medicine | 7.2018

Nemes et al

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

The Lancet Respiratory Medicine | 4.2018

Penn-Nicholson, A., Tameris, M., Smit, E., et al.

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette–Guérin-Vaccinated Adults

Frontiers in Immunology | 3.2018

van den Berg, R. A., De Mot, L., Leroux-Roels, G., et al.

Prevalence of latent tuberculous infection among adults in the general population of Ca Mau, Viet Nam

The International Journal of Tuberculosis and Lung Disease | 3.2018

Marks, G. B., Nhung, N. V., Nguyen, T. A., et al.

Progress and challenges in TB vaccine development

F1000Research  | 2.2018

Voss, G., Casimiro, D., Neyrolles, O., et al.

Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine, Community-based active case finding for tuberculosis in rural western China: a cross-sectional study

Nature Medicine  | 1.2018

Hansen, S. G., Zak, D. E., Xu, G., et al.


Strengthening global vaccine access for adolescents and adults

Vaccine | 12.2017

Nanni, A., Meredith, S., Gati, S., et al.

Impact of Targeted Tuberculosis Vaccination Among Mining Population in South Africa: A Model-Based Study

American Journal of Epidemiology | 12.2017

Shrestha, S., Chihota, V., White, R. G., et al.

Community-based active case finding for tuberculosis in rural western China: a cross-sectional study

The International Journal of Tuberculosis and Lung Disease | 11.2017

 Chen, C., Yang, C-G., Gao, X., et al.

Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population

PLOS One | 9.2017

Baguma, R., Penn-Nicholson, A., Smit, E., et al.

The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010–2014

Clinical and Vaccine Immunology | 9.2017

Brennan, M. J., Tanner, R., Morris, S., et al. 

Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection

American Journal of Respiratory and Critical Care Medicine  | 9.2017

Nemes, E., Rozot, V., Geldenhuys, H., et al.

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination

The International Journal of Tuberculosis and Lung Disease | 7.2017

 Bunyasi, E. W., Luabeya, A. K. K., Tameris, M., et al.


The enigmatic PE/PPE multigene family of mycobacteria and tuberculosis vaccination

Infection and Immunity | 6.2017

Brennan, M. J., Maurelli, A. T.

Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901

PLOS One | 5.2017

Von Reyn, C. F., Lahey, T., Arbeit, R. D., et al. 

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial

American Journal of Respiratory and Critical Care Medicine | 5.2017

van Zyl-Smit, R. N., Esmail, A., Bateman, M. E., et al.

Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 100 Luo infants from the Boro area of Nyanza Province, Kenya

Human Immunology | 4.2017

Arlehamn, C. S. L., Copin, R., Leary, S., et al.

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study

The Lancet | 4.2017

Andrews, J. R., Nemes, E., Tameris, M., et al.

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I does escalation trials

Vaccine | 3.2017

Norrby, M., Vesilkari, T., Lindqvist, L., et al.


Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine

Scientific Reports | 11.2016

Nyendak, M., Swarbrick G.M., Duncan A., et al.


Nature Reviews Disease Primers | 10.2016

Pai, M., Behr M.A., Dowdy, D., et al.

Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled by Host Genotype

American Society for Microbiology | 9.2016

Smith, C.M., Proulx M.K., Olive A.J., et al.

A new tool for tuberculosis vaccine screening:  Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis

BMC Infectious Diseases | 8.2016

Zelmer, A., Tanner, R., Stylianou, E., et al.

Advocacy, partnership and political commitment for TB vaccine research

Tuberculosis | 8.2016

Oleson, O.F., Chan, S., Chappell, J., Guo, Y., Leite, L.C.C.

Epidemiologic studies and novel clinical research approaches that impact TB vaccine development

Tuberculosis | 8.2016

Evans, T.G., Churchyard, G.J., Penn-Nicholson, A.P., et al.

TB biomarkers, TB correlates and human challenge models: New tools for improving assessment of new TB vaccines

Tuberculosis | 8.2016

Kaufmann, S.H.E., Fortune, S., Pepponi, I., Ruhwald, M., Schrager, L.K., Ottenhoff, T.H.M.

Immunopathogenesis of tuberculosis and novel mechanisms of vaccine activity

Tuberculosis | 8.2016

Schrager, L.K., Izzo, A., Velmurugan, K.

Novel approaches to preclinical research and TB vaccine development

Tuberculosis | 8.2016

Walker, K.B., Guo, M., Guo, Y., Poecheim, J., Velmurugan, K., Schrager, L.K.

TB vaccines in clinical development

Tuberculosis | 8.2016

Ginsberg, A.M., Ruhwald, M., Mearns, H., McShane, H.

Incidence of tuberculosis among school-going adolescents in South India

BMC Public Health | 7.2016

Uppada, D.R., Selvam, S., Jesuraj, N., et al.

Drug-resistant TB: deadly, costly and in need of a vaccine.

Transactions of the Royal Society of Tropical Medicine and Hygiene | 3.2016

Manjelievskaia J, Erck D, Piracha S, Schrager L

“Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction.” 

The Journal of Infectious Disease | 4.2016

Chen, T., Blanc, C., Elder A.Z., et al. 

“Tuberculosis and Healthcare Workers in Underresourced Settings.”

Clinical Infectious Diseases | 5.2016

Evans, T.G., Bekker, L.

“Status of vaccine research and development of vaccines for tuberculosis.”

Vaccine | 6.2016

Evans, T.G., Schrager, L., Thole, J. 

“TB vaccine development and the End TB Strategy: importance and current status.” 

Transactions of the Royal Society of Hygiene and Tropical Medicine | 4.2016

Fletcher, H.A., Schrager, L.

“T-cell activation is an immune correlate of risk in BCG vaccinated infants.” 

Nature Communications | 4.2016

Fletcher, H.A., Snowden M.A., Landry, B., et al. 

“Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.” 

EBioMedicine | 5.2016

Hoft, D.F., Blazevic, A., Selimovic, A., et al. 

“Improvements of ATP Assay as a Substitute for the CFU Method in Estimating Viable Cell Count for BCG/rBCG Vaccine Preparations.” 

Journal of Vaccines & Vaccination | 2.2016

Jin, T.H., Qu, T., Raina, A., Alexander, P., Tsao, E. 

“PE_PGRS33 Contributes to Mycobacterium tuberculosis Entry in Macrophages through Interaction with TLR2.” 

PLoS One | 3.2016

Palucci, I., Camassa, S., Cascioferro, A., et al.

“Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON®-TB Gold (+) Kenyan adults without evidence of tuberculosis.” 

Vaccine | 5.2016

Walsh, D.S., Owira, V., Polhemus, et al. 


Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children.

The Pediatric Infectious Disease Journal | 11.2015

Luabeya KK, Tameris MD, Geldenhuys HD, Mulenga H, Van Schalkwyk A, Hughes EJ, Toefey A, Scriba TJ, Hussey G, Mahomed H, McShane H, Landry B, Hanekom WA, Hatherill M.

The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children

The Pediatric Infectious Disease Journal | 11.2015

Mulenga H, Tameris MD, Luabeya KK, Geldenhuys H, Scriba TJ, Hussey GD, Mahomed H, Landry BS,Hanekom WA, McShane H, Hatherill M.

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

PLOS One | 11.2015

Sheehan S, Harris S, Satti I, Hokey D, Dheenadhayalan V, Stockdale L, Manjaly Thomas Z, Minhinnick A, Wilkie M, Vermaak S, Meyer J, O’Shea M, Pau M, Versteege I, Douoguih M, Hendriks J, Sadoff J, Landry B, Moss P, McShane H

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Human Vaccines & Immunotherapeutics | 8.2015

Graves AJ, Hokey DA

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.

Vaccine | 8.2015

Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M3,Mahomed H, Hanekom WA, Andersen P, Scriba TJ; H56-032 Trial Study Group, Schoeman E, Krohn C, Day CL, Africa H, Makhethe L, Smit E, Brown Y, Suliman S, Hughes EJ, Bang P, Snowden MA, McClain B, Hussey GD.

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.

Vaccine | 7.2015

Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Shi Z, Bennett S, Andersen P, Kromann I, Hoff ST, Hanekom WA, Mahomed H, Hatherill M, Scriba TJ; H4:IC31 Trial Study Group, van Rooyen M, Bruce McClain J, Ryall R, de Bruyn G

Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA, November 7, 2014.

Vaccine | 6.2015

Vaccine Prevention of Sustained Mycobacterium tuberculosis Infection Summary Group.

Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014.

Vaccine | 6.2015

Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group

Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014.

Vaccine | 6.2015

Aerosol Vaccines for Tuberculosis Workshop Summary Group

Innovative clinical trial designs to rationalize TB vaccine development.

Tuberculosis | 5.2015

Ellis R, Hatherill M, Tait D, Snowden M, Churchyard G, Hanekom W, Evans T, Ginsberg A

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).

Vaccine | 4.2015

Churchyard G, Snowden M, Hokey D, Dheenadhayalan V, McClain J, Douoguih M, Pau M, Sadoff J, Landry B

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Vaccine | 3.2015

Tameris M, Hokey D, Nduba V , Sacarlal J , Laher F , Kiringa G , Gondo K , Lazarus EM , Gray GE ,Nachman S , Mahomed H , Downing K , Abel B , Scriba TJ , McClain JB , Pau MG , Hendriks J ,Dheenadhayalan V , Ishmukhamedov S , Luabeya AK , Geldenhuys H , Shepherd B , Blatner G , Cardenas V , Walker R , Hanekom WA , Sadoff J , Douoguih M , Barker L , Hatherill M

Latent Tuberculosis Infection in Rural China: Baseline Results of a Population-Based, Multicentre, Prospective Cohort Study

The Lancet Infectious Diseases | 3.2015

Lei G, Wei L, Liqiong B, Xinhua W, Jinsheng X, Antonino C, V Cárdenas, Xiangwei L, Yu Y, Jiang D, Hongtao S, Yinyin X, Mufei L, Boxuan F, Zhen L, Henan X, Rong Z, Jianmin L, Shouguo P, Fei S, Jian H, Shumin Y, Hongyan S, Yi W, Zuhui X, Yunhong T, Tianzhu C, iguo X, Hong P, Zhijian W, Tao Z, Feng Z, Haiying L, Prof Y, Prof Shiming C, Prof Qi J

Safety, Immunogenicity, and Efficacy of the Candidate Tuberculosis Vaccine MVA85A in Healthy Adults Infected with HIV-1: a Randomised, Placebo-Controlled, Phase 2 Trials

The Lancet Respiratory Medicine | 3.2015

Ndiaye BP, Thienemann F, Ota M, Landry, B, Camara M, Dieye S, Dieye TN, Esmail H, Golaith R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson K, Prof Souleymane M, Prof Robert Wilkinson, Prof H McShane

Tuberculosis vaccines: Time for a global strategy

Science Translational Medicine | 2.2015

Kaufmann S, Evans T, Hanekom W

Evaluation of the Pharmacokinetic Interaction Between Repeated Doses of Rifapentine or Rifampin and a Single Dose of Bedaquiline in Healthy Adult Subjects

Antimicrob Agents Chemother | 2.2015

Winter H, Egizi E, Murray S, Erondu N, Ginsberg A, Rouse DJ, Severynse-Stevens D, Pauli E

Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda.

Health Research Policy and Systems | 1.2015

Ssengooba W, Gelderbloem SJ, Mboowa G, Wajja A, Namaganda C, Musoke P, Mayanja-Kizza H, Joloba ML

Engineering Soya Bean Seeds as a Scalable Platform to Produce Cyanovirin-N, a non-ARV Microbicide Against HIV

Plant Biotechnology | 1.2015

Barry R. O’Keefe, André M. Murad, Giovanni R. Vianna, Koreen Ramessar, Carrie J. Saucedo, Jennifer Wilson, Karen W. Buckheit, Nicolau B. da Cunha, Ana Claudia G. Araújo, Cristiano C. Lacorte, Luisa Madeira, James B. McMahon and Elibio L. Rech.

Return to Top


A Novel Liposomal Adjuvant System, CAF01, Promotes Long-lived Mycobacterium Tuberculosis-specific T-Cell Responses in Human

Vaccine | 12.2014

Van Dissel, J.T., Joosten, S.A., Hoff, S.T., Soonawala, D., Prins, C., Hokey, D.A., O’Dee, D.M., Graves, A.,  Thierry-Carstensen, B., Andreasen, L.V., Ruhwald, M., de Visser, A.W., Agger, E.M., Ottenhoff, T.H.M., Kromann, I., Andersen, P.

Evaluation of the Pharmacokinetic Interaction between Repeated Doses of Rifapentine or Rifampin and a Single Dose of Bedaquiline in Healthy Adult Subjects

Antimicrobial Agents Chemother. | 12.2014

Winter H, Egizi E, Murray S, Erondu N, Ginsberg A, Rouse DJ, Severynse-Stevens D, Pauli E.

Tuberculosis Vaccines and Prevention of Infection

Microbiology and Molecular Biology Reviews | 12.2014

Hawn, T.R., Day, T.A., Scriba, T.J., Hatherill, M., Hanekom, W.A., Evans, T.G., Churchyard, G.J., Kublin, J.G., Bekker, L.G., Self, S.G.

The Cyanobacterial Lectin Scytovirin Displays Potent in vitro and in vivo Activity Against Zaire Ebola Virus

Antiviral Res | 12.2014

Saucedo, C.

M.tuberculosis Erdman Infection of Rhesus Macaques of Chinese Origin

Tuberculosis | 12.2014

Zhang, J., Xian, Q., Guo, M., Huang, Z., Rao, Y., Wang, Y., Wang, X., Bao, R., Evans, T.G., Hokey, D., Sizemore, D., Ho, W.Z.

Nuclear Imaging: A Powerful Novel Approach for Tuberculosis

Nuclear Medicine and B Biology | 11.2014

Johnson, D.H., Via, L.E., Kim, P., Laddy, D., Lau, C.Y., Weinstein, E.A., Jain, S.

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

NEJM | 10.2014

Gillespie SH, Crook AM, McHugh TD, Mendel CM, Ginsberg A, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ

Influence of Age and Nutritional Status on the Performance of the Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube in Young Children Evaluated for Tuberculosis in Southern India

Ped. Inf. Diseases | 10.2014

Jenum, S., Selvam, S., Mahelai, D., Jesuraj, N., Cárdenas, V., Kenneth, J., Hesseling, A.C., Doherty, T.M., Vaz, M., Grewal, H. M. S.

The Novel Tuberculosis Vaccine, AERAS-402, is Safe in Healthy Infants Previously Vaccinated with BCG, and Induces Dose-Dependent CD4 and CD8T Cell Responses

Vaccine | 10.2014

Kagina, B.M., Tameris, M.D., Geldenhuys, H., Hatherill, M., Abel, B., Hussey, G.D., Scriba, T.J., Mahomed, H., Sadoff, J.C., Hanekom, W.A.; 018-402 Clinical Lab study team, Mansoor, N., Hughes, J., de Kock, M., Whatney, W., Africa, H., Krohn, C., Veldsman, A., Kany, A.L., Douoguih, M., Pau, M.G., Hendriks, J., McClain, B., Benko, J., Snowden, M.A., Hokey, D.A

Challenges and Future in Vaccines, Drug Development, and Immunomodulatory Therapy

Annals of the American Thoracic Society | 08.2014

Kling, H.M., Nau, G.J., Ross, T.M., Evans, T.G., Chakraborty, K., Empey, K.M., Flynn, J.L.

Aerosol Vaccination with AERAS-402 Elicits Robust Cellular Immune Responses in the Lungs of Nonhuman Primates but Fails to Protect Against High-Dose Mycobacterium tuberculosis Challenge

Journal of Immunology | 08.2014

Darrah, P.A., Bolton, D.L., Lackner, A.A., Kaushal, D., Aye, P.P., Mehra, S., Blanchard, J.L., Didier, P.J., Roy, C.J., Rao, S.S., Hokey, D.A., Scanga, C.A., Sizemore, D.R., Sadoff, J.C., Roederer, M., Seder, R.A.

Evidence-to-Policy Gap on Hepatitis A Vaccine Adoption in 6 countries, Literature vs. Policymakers’ Beliefs

Vaccine | 07.2014

Ozawa, S., Privor-Dumm, L.A, Nanni, A., Durden, E., Maiese, B.A., Nwankwo, C.U., Brodovicz, K.G., Acosta, C.J., Foley, K.A.

The Frequencies of IFNγ+IL2+TNFα+ Mycobacterium tuberculosis-reactive CD4+CD45RO+ T Cells Correlate with the Magnitude of the QuantiFERON® Gold In-tube Response in a Prospective Study of Healthy Indian Adolescents

PLOS One | 06.2014

Jenum, S., Grewal, H. M. S., Hokey, D. A., Kenneth, J., Vaz, M., Doherty, T. M., & Jahnsen, F. L

Detection of E6-AP as a Potential Therapeutic Target in Cervical Specimen of HPV-infected Women

Gynecology and Obstetrics | 06.2014

Hillemanns, P., Jentschke, M,, Evans, T.G., Soergel, P., Hass, R.

Multivalent TB Vaccines Targeting the esx Gene Family Generate Potent and Broad Cell-Mediated Immune Responses Superior to BCG

Human Vaccines and Immunotherapeutics | 06.2014

Villarreal, D.O., Walters, J., Laddy, D.J., Yan, J., Weiner, D.B.

OMIP-022: Comprehensive Assessment of Antigen-Specific Human T-Cell Functionality and Memory


Andrew J. Graves, Marcelino G. Padilla, David A. Hokey

Critical Research Concepts in TB Vaccine Development

Clinical Microbiology and Infection | 05.2014

Delogu, G., Manganelli, R., Brennan, M.J.

A Nonhuman Primate Toxicology and Immunogenicity Study Evaluating Aerosol Delivery of AERAS-402/Ad35 Vaccine: Evidence For Transient T Cell Responses in Peripheral Blood and Robust Sustained Responses in the Lungs


David A Hokey, Robert Wachholder, Patricia A Darrah, Diane L Bolton,  Dan H Barouch, Krystal Hill, Veerabadran Dheenadhayalan, Stephan Schwander, C Steven Godin, Macaya Douoguih, Maria Grazia Pau, Robert A Seder, Mario Roederer, Jerald C Sadoff, Donata Sizemore

Novel Licensure Pathways for Expeditious Introduction of New Tuberculosis Vaccines: A Discussion of the Adaptive Licensure Concept


Roxana Rustomjee, Stephen Lockhart, Jacqueline Shea, P. Bernard Fourie, Zoë Hindle, Gavin Steel, Gregory Hussey, Ann Ginsberg, and Michael J. Brennan

Differential Inhibitory Effects of Cyanovirin-N, Griffithsin, and Scytovirin , on Entry Mediated by Envelopes of Gammaretroviruses and Deltaretroviruses

Journal of Virology | 02.2014

Saucedo, C.

TB Vaccines: The (Human) Challenge Ahead


David Hokey

Multimedia Educational Tool Increases Knowledge of Clinical Trials in Uganda

Journal of Clinical Research and Bioethics | 01.2014

Castelnuovo, B., Newell, K.; Manabe, Y.C., Robertson, G


Critical Research Concepts in TB Vaccine Development


Delogu G, Manganelli R, Brennan MJ.

View the Publication

Inhibition of Mycobacterial Growth In Vitro Following Primary but Not Secondary Vaccination with Mycobacterium bovis BCG


Helen A. Fletcher, Rachel Tanner, Robert S. Wallis, Joel Meyer, Zita-Rose Manjaly, Stephanie Harris, Iman Satti, Richard F. Silver, Dan Hoft, Beate Kampmann, K. Barry Walker, Hazel M. Dockrell, Uli Fruth, Lew Barker, Michael J. Brennan, and Helen McShane

View the Publication

Tuberculosis, HIV, and Type 2 Diabetes Mellitus: A Neglected Priority


Tolu Oni, Kari Stoever, Robert J Wilkinson

View the Publication

Powder Vaccines for Pulmonary Delivery


Tom Jin, Eric Tsao

View the Publication

The Current State of Tuberculosis Vaccines


Hokey D, Ginsberg A

View the Publication

Identification of Growth Promoting Effect of rBCG/BCG Culture Supernatant and Its Potential Applications


Tom H. Jin, Tianli Qu, Anant Raina, Eric Tsao

View the Publication

Preventive Vaccines for Tuberculosis

VACCINE | 4.18.2013

Thomas G. Evans, Michael J. Brennan, Lew Barker, Jelle Thole

View the Publication

Nonclinical Development of BCG Replacement Vaccine Candidates

VACCINES | 4.15.2013

Kamalakannan Velmurugan, Leander Grode, Rosemary Chang, Megan Fitzpatrick, Dominick Laddy, David Hokey, Steven Derrick, Sheldon Morris, David McCown, Reginald Kidd, Martin Gengenbacher, Bernd Eisele, Stefan H.E. Kaufmann, John Fulkerson, Michael J. Brennan

View the Publication

An Urgent Call for a Stronger, Louder Voice for TB Vaccine Advocacy

TUBERCULOSIS | 3.13.2013

Tameris M, Gelderbloem SJ, Rustomjee R.

View the Publication

Lessons Learnt from the First Efficacy Trial of a New Infant Tuberculosis Vaccine Since BCG


Michele Tameris, Helen McShane, J. Bruce McClain, Bernard Landry, Stephen Lockhart, Angelique K.K. Luabeya, Hennie Geldenhuys, Jacqui Shea, Greg

View the Publication

Comparing the Safety and Immunogenicity of a Candidate TB Vaccine MVA85A Administered by Intramuscular and Intradermal Delivery

VACCINE | 2.03.2013

Meyer et al.

View the Publication

Safety and Efficacy of MVA85A, a New Tuberculosis Vaccine,in Infants Previously Vaccinated with BCG: a Randomised, Placebo-controlled Phase 2b Trial

THE LANCET | 2.03.2013

Michele D Tameris*, Mark Hatherill*, Bernard S Landry, Thomas J Scriba, Margaret Ann Snowden, Stephen Lockhart, Jacqueline E Shea

View the Publication

Induction and Regulation of T Cell Immunity by the Novel TB Vaccine M72/AS01 in South African Adults


Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori

View the Publication

Return to Top


A Rational Vaccine Pipeline for Tuberculosis


Brennan MJ, Stone M, Evans T

View the Publication

Designing an Adaptive Phase II/III Trial to Evaluate Efficacy, Safety and Immune Correlates of New TB Vaccines in Young Adults and Adolescents

TUBERCULOSIS | 11.26.2012

R. Rustomjee, B. McClain, M.J. Brennan, R. Mcleod, C.M. Chetty-Makkan, H. McShane, W. Hanekom, G. Steel, H. Mahomed, A.M. Ginsberg, J. Shea, S. Lockhart, S. Self, G.J. Churchyard

View the Publication

Lessons Learned in Shaping Vaccine Markets in Low-Income Countries: A Review of the Vaccine Market Segment Supported by the GAVI Alliance


Shawn A.N. Gilchrist and Angeline Nanni

View the Publication

Impact of Structural Domains of the Heparin Binding Hemagglutinin of Mycobacterium tuberculosis on Function.


Delogu G, Fadda G, Brennan MJ

View the Publication

Deciphering the Proteome of the In Vivo Diagnostic Reagent “Purified Protein Derivative” from Mycobacterium tuberculosis

PROTEOMICS | 4.20.2012

Cho YS, Dobos KM, Prenni J, Yang H, Hess A, Rosenkrands I, Andersen P, Ryoo SW, Bai GH, Brennan MJ, Izzo A, Bielefeldt-Ohmann H, Belisle JT

View the Publication

Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade


Michael J. Brennan and Jelle Thole

View the Publication

Rational Approach to Selection and Clinical Development of TB Vaccine Candidates


Lew Barker, Luc Hessell, Barry Walker

View the Publication

Preclinical Evidence for Implementing a Prime-Boost Vaccine Strategy for Tuberculosis

VACCINE | 3.02.2012

Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, Izzo AA, Barker LF.

View the Publication

Disruption of the ESX-5 System ofMycobacterium tuberculosis Causes Loss of PPE Protein Secretion, Reduction of Cell Wall Integrity and Strong Attenuation.


Bottai D, Di Luca M, Majlessi L, Frigui W, Simeone R, Sayes F, Bitter W, Brennan MJ, Leclerc C, Batoni G, Campa M, Brosch R, Esin S

View the Publication

A Recombinant Adenovirus Expressing Immunodominant TB Antigens Can Significantly Enhance BCG-Induced Human Immunity.

VACCINE | 1.28.2012

Hoft DF, Blazevic A, Stanley J, Landry B, Sizemore D, Kpamegan E, Gearhart J, Scott A, Kik S, Pau MG, Goudsmit J, McClain JB, Sadoff J.

View the Publication

A Phase IIa Trial of the New TB Vaccine, MVA85A, in HIV and/or M. Tuberculosis Infected Adults.


Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Makhethe L, van Rensburg EJ, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hawkridge A, Hussey GD, Hanek

View the Publication

Return to Top


Tuberculosis Vaccines: Review of Current Development Trends and Future Challenges


Graves A, Hokey DA

View the Publication

Optimizing HIV-1-Specific CD8+ T-cell Induction by ReCombinant BCG in Prime-Boost Regimens with Heterologous Viral Vectors.


Hopkins R, Bridgeman A, Bourne C, Mbewe-Mvula A, Sadoff JC, Both GW, Joseph J, Fulkerson J, Hanke T.

View the Publication

Immune Modulation Through 4-1BB Enhances SIV Vaccine Protection in Non-human Primates against SIVmac251 Challenge.

PLOS ONE | 9.14.2011

Hirao LA, Hokey DA, Morrow MP, Jure-Kunkel MN, Weiner DB

View the Publication

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A

PLOS ONE | 8.25.2011

Griffiths et al.

View the Publication

Improved Formulation and Lyophilization Cycle for rBCG Vaccine

VACCINE | 6.24.2011

Tom H. Jin, Lisa Nguyen, Tianli Qu, Eric Tsao

View the Publication

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants


Ota et al.

View the Publication

Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants


Scriba et al.

View the Publication

The Challenges Of Developing New Tuberculosis Vaccines

HEALTH AFFAIRS | 6.08.2011

Barker L, Leadman A, Clagett B

View the Publication

Return to Top


HLA-A*3001 and A*3002 Show Distinct Peptide Binding Patterns of the Mycobacterium tuberculosis Protein TB10.4: Consequences for Immune Recognition


Axelsson-Robertson R, Ahmed RK, Weichold FF, Ehlers MM, Kock MM, Sizemore D, Sadoff J, Maeurer M. (2010).

View the Publication

The Induction of Cell Death After Localization to the Host Cell Mitochondria by the Mycobacterium tuberculosis PE_PGRS33 Protein

MICROBIOLOGY | 11.15.2010

Cadieux N, Parra M, Cohen H, Maric D, Morris S, Brennan M

View the Publication

Aerosol Vaccines for Tuberculosis: A Fine Line Between Protection and Pathology

TUBERCULOSIS (EDINB.) | 11.07.2010

Hokey DA, Misra A

View the Publication

Prospects for a New, Safer, and More Effective TB Vaccine


Hawkridge T, Mahomed H

View the Publication

The Non-Pathogenic Mycobacteria M. smegmatis and M. fortuitum Induce Rapid Host Cell Apoptosis Via a Caspase-3 and TNF Dependent Pathway.


Bohsali A, Abdalla H, Velmurugan K, Briken V.

View the Publication

New Vaccines for Tuberculosis

THE LANCET | 6.11.2010

Kaufmann S, Hussey G, Lambert PH

View the Publication

High Content Cellular Immune Profiling Reveals Differences Between Rhesus Monkeys and Men

IMMUNOLOGY | 5.25.2010

Magalhaes I, Vudattu NK, Ahmed RK, Kühlmann-Berenzon S, Ngo Y, Sizemore DR, Wehlin L, Weichold F, Andersson J, Skeiky YAW, Sadoff J, Gaines H, Thorstensson R, Spångberg M, Maeurer MJ

View the Publication

Investigating the Induction of Vaccine Induced Th17 1 and Regulatory T Cells in Healthy, BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A


de Cassan et al.

View the Publication

Update on Research and Development Pipeline: Tuberculosis Vaccines


Beresford B, Sadoff JC

View the Publication

Stabilizing Formulations for Inhalable Powders of an Adenovirus 35-vectored Tuberculosis (TB) Vaccine (AERAS-402)

VACCINE | 5.01.2010

Jin TH, Tsao E, Goudsmit J, Dheenadhayalan V, Sadoff J.

View the Publication

Structured Approaches For the Screening and Diagnosis of Childhood Tuberculosis in a High Prevalence Region of South Africa


M Hatherill, M Hanslo,T Hawkridge,F Little, L Workman, H Mahomed, M Tameris,S Moyo, H Geldenhuys, W Hanekom,L Geiter,and G Hussey

View the Publication